Life science stocks are under pressure due to possible NIH funding cuts. What lies ahead for the sector
A recent move by the Trump administration to substantially lower funding from the National Institutes of Health for research institutions around the country has investors fearing meaningful losses for life science tools companies. The NIH announced in early February that it would cap research funding at 15% for “indirect costs” – those that aren’t directly … Read more
